SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC

NCT07131319 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

OTHER: Spatially Fractionated Radiotherapy (SFRT)
DRUG: Tislelizumab, Carboplatin, Pemetrexed
DRUG: Tislelizumab, paclitaxel, Carboplatin

Sponsor

Second Affiliated Hospital of Nanchang University